Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Science

European pressure cooker for start-ups finishes at YesDelft

Ten handpicked medtech start-ups followed the two-month EIT Health Validation Lab, which finished in Delft last week. What have they learned?

Medtech startups at YesDelft, Tope Agbana in the middle. (Photo: YesDelft)

Over the course of eight weeks 10 start-ups travelled through the Netherlands and across Europe to validate the business potential of their ideas with leading universities, healthcare companies and hospitals. This 3rd edition of the EIT Health (European Institute of Technology) Validation Lab was a partnership between EIT Health and YesDelft. It aims to help promising start-ups in medical technology to validate their products in close collaboration with their mentors and industry specialists.


TU Delta asked the three top-ranking participants how they felt about the experience and what they had learned.


Enlarging user group 

Justin Fourie from Gyrafit thinks the two months were “exceptionally well spent”. Gyrafit makes insoles that can be adjusted to individual needs (check video for animation). One lesson for Gyrafit was to meet the market’s wishes instead of rolling out its own ideas. This helped it to find a new entry point to the market. It used to focus on podiatrists to prescribe its product, but now it is targeting physiotherapists, thereby reducing the number of people in the chain, while simultaneously targeting a larger user group.


Strategic alliance

EYE MIC
develops systems to track eye-movements for controlling instruments. A surgeon could thus guide the operation microscope just by staring at the next target. Felix Karch from Germany says the validation lab was “super valuable”.

He appreciated the collaboration between the start-ups and the mutual feedback,  and he feels that they have built up a good network. Just like Gyrafit, EYE MIC has changed its customer group. Originally it targeted users, like eye surgeons for instance. But after realising that users are not generally the buyers, it decided to direct its attention at microscope manufacturers, which may add the EYE MIC as a valuable add-on. Felix estimates its company will need another two years to get to the market stage.


Where is the pain?

“A scientist is always in the lab”, explains Temitope Agbana from Smart Medical Optics. “We bond with the technology. In this validation lab we learned to check whether the technology is relevant to the world. We ask ourselves where is the gap it can fill, where the pain it can soothe?”  Smart Medical Optics run by Agbana, Mirte Vendel and Professor Gleb Vdovin, emerged as overall winner of the validation lab. It uses  a combination of multimodal imaging platform and integrated  smart algorithm to diagnose tropical diseases like malaria with reduced human intervention.


In the validation lab, Agbana discovered that his first customers may be closer than he thought. He developed the diagnostics tool with Nigeria, his homeland, in mind. But it turned out that academic and private institutions in the Netherlands working on developing malaria medications were desperate for a better optical instrument  that can rapidly quantify parasitemia for their malaria culture. Another discovery was that NGOs with their headquarters in London or the Netherlands were keen to partner up to validate the technique in the field. Needless to say that their help simplifies logistics enormously.


The part of the EIT Health Validation Lab he liked most were the honest peer to peer feedback within the group and the camaraderie on the move. The members got so close that in the end they could do each other’s pitches. In fact, Agbana came close to selling one of the other participants’ products, he says laughingly.

Science editor Jos Wassink

Do you have a question or comment about this article?

j.w.wassink@tudelft.nl

Comments are closed.